Page last updated: 2024-11-02

pirenzepine and Metabolic Diseases

pirenzepine has been researched along with Metabolic Diseases in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Griffiths, J1
Springuel, P1

Reviews

1 review available for pirenzepine and Metabolic Diseases

ArticleYear
Atypical antipsychotics: impaired glucose metabolism.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Oct-02, Volume: 165, Issue:7

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Glucose;

2001